Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis („NASH“) to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/eternygen-announces-the-first-closing-of-its-series-a2-funding-round-5988
Just – Evotec Biologics receives grant to enable an antibody product for the prevention of COVID-19
Evotec SE today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (“mAb”) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-receives-grant-to-enable-an-antibody-product-for-the-prevention-of-covid-19-5984
Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing and appoints Klaus Martin, Ph.D. as Chief Executive Officer
Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/topas-therapeutics-raises-eur-22-m-us-26-m-in-series-b-financing-and-appoints-klaus-martin-phd-as-chief-executive-officer-5987
Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE
Evotec SE today announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/mubadala-investment-company-and-novo-holdings-as-invest-eur-250-million-in-evotec-se-5980
MUBADALA INVESTMENT COMPANY AND NOVO HOLDINGS A/S INVEST € 250 M IN EVOTEC SE
Evotec SE today announced that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec’s cash reserves by € 250 million in total. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/mubadala-investment-company-and-novo-holdings-as-invest-eur-250-m-in-evotec-se-5983
Evotec achieves milestone in neurodegeneration collaboration with Bristol Myers Squibb
Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company following the decision to expand the portfolio by another drug discovery project. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-neurodegeneration-collaboration-with-bristol-myers-squibb-5978
Symrise HOGO: Suchplattform zur Auswahl von Inhalts-stoffen für modernen Produktschutz
— Unterstützt Formulierer von Kosmetika bei der Auswahl geeigneter schützender Inhaltsstoffe
— Zusätzliche Informationen zu Dosierungs- und Wirksamkeitsdaten
— Geht am 1. Oktober 2020 online Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-hogo-suchplattform-zur-auswahl-von-inhalts-stoffen-fuer-modernen-produktschutz/
Symrise bringt Kunden und Verbraucher direkt an den Ursprung der Vanille aus Madagaskar
— Höchste Vanille-Qualität und sicheren Zugang zum Rohstoff
— Transparente, rückverfolgbare Wertschöpfungskette & Stärkung lokaler Erzeuger
— Beitrag zu den UN-Zielen nachhaltiger Entwicklung Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-bringt-kunden-und-verbraucher-direkt-an-den-ursprung-der-vanille-aus-madagaskar-1/
Symrise: Diana Food bringt erstes Acerola-Pulver mit Bio- und Fair-Trade-Zertifikat auf den Markt
— Adressiert steigende Verbrauchernachfrage nach fairen und gesunden Inhaltsstoffen
— Rohstoffe höchster Qualität aus Brasilien
— Erster Anbieter der Branche mit zertifiziertem Acerolapulver aus fairem Handel Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-diana-food-bringt-erstes-acerola-pulver-mit-bio-und-fair-trade-zertifikat-auf-den-markt/
Evotec and BIOASTER partner to build a technology and innovation hub in Lyon
Evotec SE and the French-based BIOASTER Technological Research Institute today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bioaster-partner-to-build-a-technology-and-innovation-hub-in-lyon-5975